Hong Kong—Austar Lifesciences Limited (AUSTAR) has filed its Monthly Return for the period ended 31 October 2026, confirming no changes to its share capital structure.
The authorised share capital remains at 10.00 billion ordinary shares with a par value of HKD 0.01 each, representing HKD 100.00 million in aggregate. Issued shares were unchanged at 512.58 million, and the company continues to hold zero treasury shares.
AUSTAR affirmed that it met the Hong Kong Stock Exchange’s minimum 25% public‐float requirement as of month-end. The filing also shows no share option exercises, warrant conversions, or other equity-linked movements during the month, and no Hong Kong Depositary Receipts are outstanding.
The return was submitted by Company Secretary Mak Yuk Kiu on 2 November 2026.
Comments